strategic-partnerships-en
Strategic Collaboration Agreement Signed Between Nojine Zist Pharmed and Pasteur Institute of Iran
Read Time: 3 mins
September 18, 2026
corporate-announcements-en
Commissioning of Phase II Therapeutic Albumin & Plasma Derivatives Production Line at Nojin Refinery
Date: September 18, 2026
|
Read Time: 4 mins
Following rigorous biological and technical evaluations, Nojin's advanced human plasma fractionation line was officially inaugurated, marking a transformative leap in biological therapeutics self-sufficiency.
Following the successful completion of comprehensive validation protocols and aseptic qualification trials, Nojin Zist Pharmed has officially commissioned the second expansion phase of its specialized plasma fractionation refinery.
This cutting-edge industrial facility is engineered to process human plasma into vital therapeutic derivatives, specifically Human Albumin 20% (Albojin) and high-titer Intravenous Immunoglobulins (IVIg). Operating under stringent cleanroom Grade A/B conditions and equipped with automated viral inactivation chambers, the facility dramatically bolsters healthcare security and domestic availability of plasma-derived medicinal products (PDMPs).
Dr. Keyvan Mansouri, Chief Technical Officer, emphasized: ‘The localized commissioning of this advanced cold ethanol fractionation train guarantees reproducible yield, superior protein integrity, and absolute compliance with international pharmacopoeial standards.’
Related Research Findings
rnd-production-en
Nojine Achieves 100% Pharmacopoeial Compliance Under WHO-GMP Biological Standards
Read Time: 5 mins
September 18, 2026
events-conferences-en
Nojine Scientists Present Breakthrough Clinical Research at 25th International Congress of Pharmaceutical Biotechnology
Read Time: 4 mins
September 18, 2026